and for adults with overweight in the presence of at least one weight-related health condition like high blood pressure or heart disease
Key highlights: Average weight loss of ~12.4% in Phase 3 trials Improvements in blood pressure, triglycerides, and waist circumference Oral formulation could significantly expand accessibility and patient adoption Approved for adults with obesity or overweight plus weight-related conditions This approval represents another major shift in the rapidly growing obesity therapeutics market and increases competition with injectable treatments like Wegovy
Bezerra FSB, Silva MTO, Rezende AFS, Lopes AS, de Pinho RB, Seixas FK, Collares TV, Portela RWD, Azevedo VAC, Borsuk S (2021) Saponin-adjuvanted recombinant vaccines containing rCP00660, rCP09720 or rCP01850 proteins against Corynebacterium pseudotuberculosis infection in mice
The idea is that microdosing can: Reduce side effects: Its common to experience side effects when taking GLP-1s, especially gastrointestinal issues including nausea, vomiting, and diarrhea
What if I see blood after the injection
When you take a GLP-1 medication, it can help you feel fuller longer, slow down how quickly food leaves your stomach, and support more stable blood sugar levels